Is this your brand? Sign in to claim ownership.
Sign in to claim this brandAMEDITECH INC.
US
Last updated May 27, 2026
What AMEDITECH INC. makes
The company manufactures in vitro diagnostic (IVD) devices for detecting drugs of abuse, including rapid immunoassay kits, point-of-care testing instruments, and photometric/spectroscopic analysers. Products include handheld drug screening devices like the eREADER+ and disposable test cups (eCUP, CHECKCUP), as well as multi-drug and single-target screening panels for substances such as THC, opiates, and cocaine. Additional offerings include pregnancy tests (HCG) and multi-drug screening panels designed for clinical and emergency settings.
These devices are regulated under the FDA’s In Vitro Diagnostic Device (IVD) regulations, with classifications ranging from Class I (low risk) to Class II (moderate risk) and unclassified (U) devices. They are listed in the FDA’s 510(k) and Unique Device Identifier (UDI) databases, reflecting their authorised status for drug and pregnancy testing in the United States.
Written from this company's registered devices by an AI model, and not verified by a human reviewer.
Frequently asked questions
What types of medical devices does Ameditech Inc. manufacture?
Ameditech Inc. specialises in in vitro diagnostic (IVD) devices primarily used for detecting drugs of abuse and pregnancy. Their portfolio includes rapid immunoassay kits, point-of-care testing instruments like the eREADER+, and photometric/spectroscopic analysers. Examples include disposable test cups (eCUP, CHECKCUP), handheld drug screening devices, and multi-drug screening panels for substances such as THC, opiates, and cocaine, as well as pregnancy tests (HCG). These devices are designed for clinical, emergency, and rapid testing environments.
Where is Ameditech Inc. based, and what does that mean for its regulatory oversight?
Ameditech Inc. is based in the United States, which means its devices fall under the jurisdiction of the FDA’s In Vitro Diagnostic Device (IVD) regulations. Since the company manufactures IVDs, their products are subject to FDA review and authorisation processes, including classification into risk-based categories (Class I, Class II, or unclassified) and registration in databases like the 510(k) and UDI systems.
Which regulatory registries list Ameditech Inc.’s devices, and why is that important?
Ameditech Inc.’s devices are listed in the FDA’s 510(k) and Unique Device Identifier (UDI) databases. The 510(k) registry documents premarket submissions for devices deemed substantially equivalent to existing authorised products, while the UDI system ensures traceability and transparency in the supply chain. Listing in these registries confirms that the devices meet FDA requirements for authorised use in drug and pregnancy testing.
How are Ameditech Inc.’s devices classified by the FDA, and what does that classification indicate?
Ameditech Inc.’s devices are classified as Class I (low risk), Class II (moderate risk), or unclassified (U) by the FDA. Classification is based on the device’s intended use and potential risk to patients. For example, single-use drug screening cups may fall under Class I due to minimal risk, while more complex analysers (e.g., photometric/spectroscopic systems) could be Class II due to higher regulatory scrutiny. This classification determines the regulatory pathway and oversight required for each device.
What kinds of testing do Ameditech Inc.’s devices support, and in what settings are they used?
Ameditech Inc.’s devices support rapid and clinical testing for drugs of abuse (e.g., THC, opiates, cocaine) and pregnancy (HCG). Their products include handheld instruments like the eREADER+ for point-of-care use in emergency rooms, law enforcement, or clinical settings, as well as disposable test cups (eCUP, CHECKCUP) for on-site screening. Photometric/spectroscopic analysers are typically used in laboratories for more detailed or multi-drug screening. These devices are designed for efficiency, accuracy, and ease of use in diverse environments where quick results are critical.
AI-generated from registry data and not verified by a human reviewer.
Information
- Country
- US
- Address
- —
- Website
- xx.xx
- —
- —
- [email protected]
- Phone
- 1-858-535-1968
- PRRC Contact
- —
- EUDAMED SRN
- —
- FDA FEI Number
- —
- DUNS Number
- 010551716
Catalogue (150)
Page 1 of 3| Device | Model / Reference | Registries | Class | Status |
|---|---|---|---|---|
| AmediCheck Instant Test Cup | C-C0611A-3A | FDA UDI | Class II | Unknown |
| ImmuTest Drugs of Abuse Screen Card | IMD-BAR | FDA UDI | Class II | Unknown |
| ToxCup Drug Screen Cup | PT15-CE | FDA UDI | Class II | Unknown |
| Fastect II Drug Screen Dipstick Test | BF10 | FDA UDI | Class II | Unknown |
| ToxCup Drug Screen Cup | DT12A | FDA UDI | Class II | Unknown |
| ImmuTest Drugs of Abuse Screen Card | IMD-MET | FDA UDI | Class II | Unknown |
| QuickTox Drug Screen Dipcard | QT44 | FDA UDI | Class II | Unknown |
| ImmuTest Drugs of Abuse Cup | IMCA-7P | FDA UDI | Class II | Unknown |
| ImmuTest Drugs of Abuse Cup | IMCA-10M5 | FDA UDI | Class II | Unknown |
| ImmuTest Drugs of Abuse Screen Card | IMD-AMP | FDA UDI | Class II | Unknown |
| Instant Test Cup | 10-100 | FDA UDI | Class II | Unknown |
| Fastect II Drug Screen Dipstick Test | MF11 | FDA UDI | Class II | Unknown |
| ImmuTest Drugs of Abuse Screen Card | IMD-12MO3 | FDA UDI | Class II | Unknown |
| ImmuTest Drugs of Abuse Screen Device | IMDA-3AMJ | FDA UDI | Class II | Unknown |
| AmediCheck Instant Test Cup | C-C1202A | FDA UDI | Class II | Unknown |
| ToxCup Drug Screen Cup | HT21 | FDA UDI | Class II | Unknown |
| ToxCup Drug Screen Cup | DT10A-CE | FDA UDI | Class II | Unknown |
| Fastect II Drug Screen Dipstick Test | MF22 | FDA UDI | Class II | Unknown |
| ImmuTest Drugs of Abuse Screen Card | IMDA-5M | FDA UDI | Class II | Unknown |
| AmediCheck Instant Test Cup | C-60B02 | FDA UDI | Class II | Unknown |
| QuickTox Drug Screen Dipcard | QT13 | FDA UDI | Class II | Unknown |
| QuickTox Drug Screen Dipcard | QT88 | FDA UDI | Class II | Unknown |
| QuickTox Drug Screen Dipcard | QT20A | FDA UDI | U | Unknown |
| QuickTox Drug Screen Dipcard | QT63 | FDA UDI | Class II | Unknown |
| QuickTox Drug Screen Dipcard | QT13-CE | FDA UDI | Class II | Unknown |
| ImmuTest Drugs of Abuse Screen Card | IMD-COC | FDA UDI | Class II | Unknown |
| ImmuTest Drugs of Abuse Cup | IMCA-5P | FDA UDI | Class II | Unknown |
| Instant Test Cup | 10-200 | FDA UDI | Class II | Unknown |
| ImmuTest Drugs of Abuse Screen Card | IMDA-2AMJ | FDA UDI | Class II | Unknown |
| ImmuTest Drugs of Abuse Cup | IMC-7P | FDA UDI | Class II | Unknown |
| ImmuTest Drugs of Abuse Cup | IMCA-9CM5 | FDA UDI | Class II | Unknown |
| ImmuTest Drugs of Abuse Screen Card | IMD-8MT | FDA UDI | Class II | Unknown |
| ToxCup Drug Screen Cup | HT23 | FDA UDI | Class II | Unknown |
| QuickTox Drug Screen Dipcard | QT54 | FDA UDI | Class II | Unknown |
| ImmuTest Drugs of abuse Cup | IMCA-5M | FDA UDI | Class II | Unknown |
| Fastect II Drug Screen Dipstick Test | QF08 | FDA UDI | Class II | Unknown |
| ImmuTest Drugs of Abuse Cup | IMCA-5BO3 | FDA UDI | Class II | Unknown |
| ToxCup Drug Screen Cup | PT13 | FDA UDI | Class II | Unknown |
| ToxCup Drug Screen Cup | PT23A-CE | FDA UDI | Class II | Unknown |
| QuickTox Drug Screen Dipcard | QT15-CE | FDA UDI | Class II | Unknown |
| Immutest Drugs of Abuse Screen Device | IMDA-9AMJ | FDA UDI | Class II | Unknown |
| ImmuTest Drugs of Abuse Screen Card | IMDA-3M | FDA UDI | Class II | Unknown |
| ImmuTest Drugs of Abuse Cup | IMCA-13M | FDA UDI | Class II | Unknown |
| ToxCup Drug Screen Cup | PT11 | FDA UDI | Class II | Unknown |
| QuickTox Drug Screen Dipcard | QT80F-CE | FDA UDI | Class II | Unknown |
| QuickTox Drug Screen Dipcard | QT23A | FDA UDI | Class II | Unknown |
| QuickTox Drug Screen Dipcard | QT23 | FDA UDI | U | Unknown |
| QuickTox Drug Screen Dipcard | QT15 | FDA UDI | Class II | Unknown |
| Oratect Oral Fluid Collection Tube | CM-190 | FDA UDI | U | Unknown |
| ImmuTest Drugs of Abuse Cup | IMCA-12BUP | FDA UDI | Class II | Unknown |
Related Companies
Authorised Representatives
No authorised representatives on record.
Importers
Not available yet.
Notified Bodies
Not available yet.
Authorities
Not available yet.
FDA Recalls (100)
Recalls reported by this firm to the FDA. Listed at company level — FDA recall records don't identify a specific catalogue device.
Ameditech Inc. has 109 recall records initiated between September 23, 2014, and August 18, 2020, all marked as terminated. The reasons cited include labeling errors—such as incorrect identification of drug analytes (e.g., PCP instead of TCA)—and performance failures, including inconsistent detection of calibrators and secondary compounds due to enzyme issues. Additional recalls involved missing components, incorrect illustrations on packaging, and reduced reactivity in drug tests for specific compounds like certain benzodiazepines. Some records also noted mixed product shipments with incorrect or mismatched part numbers and lot numbers.
AI-generated summary of the recall records listed below. It describes what the records state and is not an assessment of this manufacturer.
| Date | Recall No. | Class | Status | Reason |
|---|---|---|---|---|
| Aug 18, 2020 | Z-3042-2020 | — | terminated | Various immunoassay enzymes failed product performance, thereby the products do not consistently detect all calibrator and secondary compounds at the levels stated in the labeling. |
| Aug 18, 2020 | Z-3045-2020 | — | terminated | Various immunoassay enzymes failed product performance, thereby the products do not consistently detect all calibrator and secondary compounds at the levels stated in the labeling. |
| Aug 18, 2020 | Z-3041-2020 | — | terminated | XXX |
| Aug 18, 2020 | Z-3030-2020 | — | terminated | Various immunoassay enzymes failed product performance, thereby the products do not consistently detect all calibrator and secondary compounds at the levels stated in the labeling. |
| Aug 18, 2020 | Z-3039-2020 | — | terminated | Various immunoassay enzymes failed product performance, thereby the products do not consistently detect all calibrator and secondary compounds at the levels stated in the labeling. |
| Aug 18, 2020 | Z-3046-2020 | — | terminated | Various immunoassay enzymes failed product performance, thereby the products do not consistently detect all calibrator and secondary compounds at the levels stated in the labeling. |
| Aug 18, 2020 | Z-3029-2020 | — | terminated | Various immunoassay enzymes failed product performance, thereby the products do not consistently detect all calibrator and secondary compounds at the levels stated in the labeling. |
| Aug 18, 2020 | Z-3040-2020 | — | terminated | Various immunoassay enzymes failed product performance, thereby the products do not consistently detect all calibrator and secondary compounds at the levels stated in the labeling. |
| Aug 18, 2020 | Z-3036-2020 | — | terminated | Various immunoassay enzymes failed product performance, thereby the products do not consistently detect all calibrator and secondary compounds at the levels stated in the labeling. |
| Aug 18, 2020 | Z-3033-2020 | — | terminated | Various immunoassay enzymes failed product performance, thereby the products do not consistently detect all calibrator and secondary compounds at the levels stated in the labeling. |
| Aug 18, 2020 | Z-3047-2020 | — | terminated | Various immunoassay enzymes failed product performance, thereby the products do not consistently detect all calibrator and secondary compounds at the levels stated in the labeling. |
| Aug 18, 2020 | Z-3051-2020 | — | terminated | Various immunoassay enzymes failed product performance, thereby the products do not consistently detect all calibrator and secondary compounds at the levels stated in the labeling. |
| Aug 18, 2020 | Z-3032-2020 | — | terminated | Various immunoassay enzymes failed product performance, thereby the products do not consistently detect all calibrator and secondary compounds at the levels stated in the labeling. |
| Aug 18, 2020 | Z-3049-2020 | — | terminated | Various immunoassay enzymes failed product performance, thereby the products do not consistently detect all calibrator and secondary compounds at the levels stated in the labeling. |
| Aug 18, 2020 | Z-3043-2020 | — | terminated | Various immunoassay enzymes failed product performance, thereby the products do not consistently detect all calibrator and secondary compounds at the levels stated in the labeling. |
| Aug 18, 2020 | Z-3037-2020 | — | terminated | Various immunoassay enzymes failed product performance, thereby the products do not consistently detect all calibrator and secondary compounds at the levels stated in the labeling. |
| Aug 18, 2020 | Z-3031-2020 | — | terminated | Various immunoassay enzymes failed product performance, thereby the products do not consistently detect all calibrator and secondary compounds at the levels stated in the labeling. |
| Aug 18, 2020 | Z-3044-2020 | — | terminated | Various immunoassay enzymes failed product performance, thereby the products do not consistently detect all calibrator and secondary compounds at the levels stated in the labeling. |
| Aug 18, 2020 | Z-3034-2020 | — | terminated | Various immunoassay enzymes failed product performance, thereby the products do not consistently detect all calibrator and secondary compounds at the levels stated in the labeling. |
| Aug 18, 2020 | Z-3035-2020 | — | terminated | Various immunoassay enzymes failed product performance, thereby the products do not consistently detect all calibrator and secondary compounds at the levels stated in the labeling. |
| Aug 18, 2020 | Z-3048-2020 | — | terminated | Various immunoassay enzymes failed product performance, thereby the products do not consistently detect all calibrator and secondary compounds at the levels stated in the labeling. |
| Aug 18, 2020 | Z-3050-2020 | — | terminated | Various immunoassay enzymes failed product performance, thereby the products do not consistently detect all calibrator and secondary compounds at the levels stated in the labeling. |
| Aug 18, 2020 | Z-3038-2020 | — | terminated | Various immunoassay enzymes failed product performance, thereby the products do not consistently detect all calibrator and secondary compounds at the levels stated in the labeling. |
| Feb 15, 2019 | Z-0692-2020 | — | terminated | Mixed Products containing QuickTox 5 Panel Drugs Screen Dipcard (P/N QT11, LOT #188787) and Alere iScreen Drugs of Abuse Dip Test (P/N X11-IS10-22015-DX LOT #188744) |
| Dec 15, 2017 | Z-1542-2018 | — | terminated | The kit box label incorrectly identifies Phencyclidine (PCP), where it should list Tricyclic Antidepressants (TCA) as one of the 10 drug analytes included in the kit box. |
| Sep 30, 2017 | Z-0270-2019 | — | terminated | Product was released to market without the adulteration strip included in the product. |
| Jun 26, 2017 | Z-3084-2017 | — | terminated | The kit box label incorrectly identifies PCP (instead of TCA) as one of the 10 drug analytes included in the kit. The pouch label, product insert, and the device itself are labeled correctly. |
| Nov 16, 2015 | Z-0524-2016 | — | terminated | Ameditechs Drugs of Abuse Tests listed above have shown reduced reactivity for up to two (2) of the nineteen (19) Benzodiazepine (BZO) compounds for which specificity information is provided in the product insert. The particular BZO compounds for which there may be reduced reactivity are Clonazepam and Chlordiazepoxide. |
| Nov 16, 2015 | Z-0527-2016 | — | terminated | Ameditechs Drugs of Abuse Tests listed above have shown reduced reactivity for up to two (2) of the nineteen (19) Benzodiazepine (BZO) compounds for which specificity information is provided in the product insert. The particular BZO compounds for which there may be reduced reactivity are Clonazepam and Chlordiazepoxide. |
| Nov 16, 2015 | Z-0514-2016 | — | terminated | Ameditechs Drugs of Abuse Tests listed above have shown reduced reactivity for up to two (2) of the nineteen (19) Benzodiazepine (BZO) compounds for which specificity information is provided in the product insert. The particular BZO compounds for which there may be reduced reactivity are Clonazepam and Chlordiazepoxide. |
| Nov 16, 2015 | Z-0538-2016 | — | terminated | Ameditechs Drugs of Abuse Tests listed above have shown reduced reactivity for up to two (2) of the nineteen (19) Benzodiazepine (BZO) compounds for which specificity information is provided in the product insert. The particular BZO compounds for which there may be reduced reactivity are Clonazepam and Chlordiazepoxide. |
| Nov 16, 2015 | Z-0494-2016 | — | terminated | Ameditechs Drugs of Abuse Tests listed above have shown reduced reactivity for up to two (2) of the nineteen (19) Benzodiazepine (BZO) compounds for which specificity information is provided in the product insert. The particular BZO compounds for which there may be reduced reactivity are Clonazepam and Chlordiazepoxide. |
| Nov 16, 2015 | Z-0522-2016 | — | terminated | Ameditechs Drugs of Abuse Tests listed above have shown reduced reactivity for up to two (2) of the nineteen (19) Benzodiazepine (BZO) compounds for which specificity information is provided in the product insert. The particular BZO compounds for which there may be reduced reactivity are Clonazepam and Chlordiazepoxide. |
| Nov 16, 2015 | Z-0517-2016 | — | terminated | Ameditechs Drugs of Abuse Tests listed above have shown reduced reactivity for up to two (2) of the nineteen (19) Benzodiazepine (BZO) compounds for which specificity information is provided in the product insert. The particular BZO compounds for which there may be reduced reactivity are Clonazepam and Chlordiazepoxide. |
| Nov 16, 2015 | Z-0493-2016 | — | terminated | Ameditechs Drugs of Abuse Tests listed above have shown reduced reactivity for up to two (2) of the nineteen (19) Benzodiazepine (BZO) compounds for which specificity information is provided in the product insert. The particular BZO compounds for which there may be reduced reactivity are Clonazepam and Chlordiazepoxide. |
| Nov 16, 2015 | Z-0492-2016 | — | terminated | Ameditechs Drugs of Abuse Tests listed above have shown reduced reactivity for up to two (2) of the nineteen (19) Benzodiazepine (BZO) compounds for which specificity information is provided in the product insert. The particular BZO compounds for which there may be reduced reactivity are Clonazepam and Chlordiazepoxide. |
| Nov 16, 2015 | Z-0530-2016 | — | terminated | Ameditechs Drugs of Abuse Tests listed above have shown reduced reactivity for up to two (2) of the nineteen (19) Benzodiazepine (BZO) compounds for which specificity information is provided in the product insert. The particular BZO compounds for which there may be reduced reactivity are Clonazepam and Chlordiazepoxide. |
| Nov 16, 2015 | Z-0496-2016 | — | terminated | Ameditechs Drugs of Abuse Tests listed above have shown reduced reactivity for up to two (2) of the nineteen (19) Benzodiazepine (BZO) compounds for which specificity information is provided in the product insert. The particular BZO compounds for which there may be reduced reactivity are Clonazepam and Chlordiazepoxide. |
| Nov 16, 2015 | Z-0529-2016 | — | terminated | Ameditechs Drugs of Abuse Tests listed above have shown reduced reactivity for up to two (2) of the nineteen (19) Benzodiazepine (BZO) compounds for which specificity information is provided in the product insert. The particular BZO compounds for which there may be reduced reactivity are Clonazepam and Chlordiazepoxide. |
| Nov 16, 2015 | Z-0525-2016 | — | terminated | Ameditechs Drugs of Abuse Tests listed above have shown reduced reactivity for up to two (2) of the nineteen (19) Benzodiazepine (BZO) compounds for which specificity information is provided in the product insert. The particular BZO compounds for which there may be reduced reactivity are Clonazepam and Chlordiazepoxide. |
| Nov 16, 2015 | Z-0487-2016 | — | terminated | Ameditechs Drugs of Abuse Tests listed above have shown reduced reactivity for up to two (2) of the nineteen (19) Benzodiazepine (BZO) compounds for which specificity information is provided in the product insert. The particular BZO compounds for which there may be reduced reactivity are Clonazepam and Chlordiazepoxide. |
| Nov 16, 2015 | Z-0521-2016 | — | terminated | Ameditechs Drugs of Abuse Tests listed above have shown reduced reactivity for up to two (2) of the nineteen (19) Benzodiazepine (BZO) compounds for which specificity information is provided in the product insert. The particular BZO compounds for which there may be reduced reactivity are Clonazepam and Chlordiazepoxide. |
| Nov 16, 2015 | Z-0484-2016 | — | terminated | Ameditechs Drugs of Abuse Tests listed above have shown reduced reactivity for up to two (2) of the nineteen (19) Benzodiazepine (BZO) compounds for which specificity information is provided in the product insert. The particular BZO compounds for which there may be reduced reactivity are Clonazepam and Chlordiazepoxide. |
| Nov 16, 2015 | Z-0500-2016 | — | terminated | Ameditechs Drugs of Abuse Tests listed above have shown reduced reactivity for up to two (2) of the nineteen (19) Benzodiazepine (BZO) compounds for which specificity information is provided in the product insert. The particular BZO compounds for which there may be reduced reactivity are Clonazepam and Chlordiazepoxide. |
| Nov 16, 2015 | Z-0509-2016 | — | terminated | Ameditechs Drugs of Abuse Tests listed above have shown reduced reactivity for up to two (2) of the nineteen (19) Benzodiazepine (BZO) compounds for which specificity information is provided in the product insert. The particular BZO compounds for which there may be reduced reactivity are Clonazepam and Chlordiazepoxide. |
| Nov 16, 2015 | Z-0499-2016 | — | terminated | Ameditechs Drugs of Abuse Tests listed above have shown reduced reactivity for up to two (2) of the nineteen (19) Benzodiazepine (BZO) compounds for which specificity information is provided in the product insert. The particular BZO compounds for which there may be reduced reactivity are Clonazepam and Chlordiazepoxide. |
| Nov 16, 2015 | Z-0536-2016 | — | terminated | Ameditechs Drugs of Abuse Tests listed above have shown reduced reactivity for up to two (2) of the nineteen (19) Benzodiazepine (BZO) compounds for which specificity information is provided in the product insert. The particular BZO compounds for which there may be reduced reactivity are Clonazepam and Chlordiazepoxide. |
| Nov 16, 2015 | Z-0526-2016 | — | terminated | Ameditechs Drugs of Abuse Tests listed above have shown reduced reactivity for up to two (2) of the nineteen (19) Benzodiazepine (BZO) compounds for which specificity information is provided in the product insert. The particular BZO compounds for which there may be reduced reactivity are Clonazepam and Chlordiazepoxide. |
| Nov 16, 2015 | Z-0534-2016 | — | terminated | Ameditechs Drugs of Abuse Tests listed above have shown reduced reactivity for up to two (2) of the nineteen (19) Benzodiazepine (BZO) compounds for which specificity information is provided in the product insert. The particular BZO compounds for which there may be reduced reactivity are Clonazepam and Chlordiazepoxide. |
| Nov 16, 2015 | Z-0490-2016 | — | terminated | Ameditechs Drugs of Abuse Tests listed above have shown reduced reactivity for up to two (2) of the nineteen (19) Benzodiazepine (BZO) compounds for which specificity information is provided in the product insert. The particular BZO compounds for which there may be reduced reactivity are Clonazepam and Chlordiazepoxide. |
| Nov 16, 2015 | Z-0507-2016 | — | terminated | Ameditechs Drugs of Abuse Tests listed above have shown reduced reactivity for up to two (2) of the nineteen (19) Benzodiazepine (BZO) compounds for which specificity information is provided in the product insert. The particular BZO compounds for which there may be reduced reactivity are Clonazepam and Chlordiazepoxide. |
| Nov 16, 2015 | Z-0516-2016 | — | terminated | Ameditechs Drugs of Abuse Tests listed above have shown reduced reactivity for up to two (2) of the nineteen (19) Benzodiazepine (BZO) compounds for which specificity information is provided in the product insert. The particular BZO compounds for which there may be reduced reactivity are Clonazepam and Chlordiazepoxide. |
| Nov 16, 2015 | Z-0506-2016 | — | terminated | Ameditechs Drugs of Abuse Tests listed above have shown reduced reactivity for up to two (2) of the nineteen (19) Benzodiazepine (BZO) compounds for which specificity information is provided in the product insert. The particular BZO compounds for which there may be reduced reactivity are Clonazepam and Chlordiazepoxide. |
| Nov 16, 2015 | Z-0488-2016 | — | terminated | Ameditechs Drugs of Abuse Tests listed above have shown reduced reactivity for up to two (2) of the nineteen (19) Benzodiazepine (BZO) compounds for which specificity information is provided in the product insert. The particular BZO compounds for which there may be reduced reactivity are Clonazepam and Chlordiazepoxide. |
| Nov 16, 2015 | Z-0531-2016 | — | terminated | Ameditechs Drugs of Abuse Tests listed above have shown reduced reactivity for up to two (2) of the nineteen (19) Benzodiazepine (BZO) compounds for which specificity information is provided in the product insert. The particular BZO compounds for which there may be reduced reactivity are Clonazepam and Chlordiazepoxide. |
| Nov 16, 2015 | Z-0537-2016 | — | terminated | Ameditechs Drugs of Abuse Tests listed above have shown reduced reactivity for up to two (2) of the nineteen (19) Benzodiazepine (BZO) compounds for which specificity information is provided in the product insert. The particular BZO compounds for which there may be reduced reactivity are Clonazepam and Chlordiazepoxide. |
| Nov 16, 2015 | Z-0505-2016 | — | terminated | Ameditechs Drugs of Abuse Tests listed above have shown reduced reactivity for up to two (2) of the nineteen (19) Benzodiazepine (BZO) compounds for which specificity information is provided in the product insert. The particular BZO compounds for which there may be reduced reactivity are Clonazepam and Chlordiazepoxide. |
| Nov 16, 2015 | Z-0501-2016 | — | terminated | Ameditechs Drugs of Abuse Tests listed above have shown reduced reactivity for up to two (2) of the nineteen (19) Benzodiazepine (BZO) compounds for which specificity information is provided in the product insert. The particular BZO compounds for which there may be reduced reactivity are Clonazepam and Chlordiazepoxide. |
| Nov 16, 2015 | Z-0512-2016 | — | terminated | Ameditechs Drugs of Abuse Tests listed above have shown reduced reactivity for up to two (2) of the nineteen (19) Benzodiazepine (BZO) compounds for which specificity information is provided in the product insert. The particular BZO compounds for which there may be reduced reactivity are Clonazepam and Chlordiazepoxide. |
| Nov 16, 2015 | Z-0491-2016 | — | terminated | Ameditechs Drugs of Abuse Tests listed above have shown reduced reactivity for up to two (2) of the nineteen (19) Benzodiazepine (BZO) compounds for which specificity information is provided in the product insert. The particular BZO compounds for which there may be reduced reactivity are Clonazepam and Chlordiazepoxide. |
| Nov 16, 2015 | Z-0485-2016 | — | terminated | Ameditechs Drugs of Abuse Tests listed above have shown reduced reactivity for up to two (2) of the nineteen (19) Benzodiazepine (BZO) compounds for which specificity information is provided in the product insert. The particular BZO compounds for which there may be reduced reactivity are Clonazepam and Chlordiazepoxide. |
| Nov 16, 2015 | Z-0503-2016 | — | terminated | Ameditechs Drugs of Abuse Tests listed above have shown reduced reactivity for up to two (2) of the nineteen (19) Benzodiazepine (BZO) compounds for which specificity information is provided in the product insert. The particular BZO compounds for which there may be reduced reactivity are Clonazepam and Chlordiazepoxide. |
| Nov 16, 2015 | Z-0489-2016 | — | terminated | Ameditechs Drugs of Abuse Tests listed above have shown reduced reactivity for up to two (2) of the nineteen (19) Benzodiazepine (BZO) compounds for which specificity information is provided in the product insert. The particular BZO compounds for which there may be reduced reactivity are Clonazepam and Chlordiazepoxide. |
| Nov 16, 2015 | Z-0533-2016 | — | terminated | Ameditechs Drugs of Abuse Tests listed above have shown reduced reactivity for up to two (2) of the nineteen (19) Benzodiazepine (BZO) compounds for which specificity information is provided in the product insert. The particular BZO compounds for which there may be reduced reactivity are Clonazepam and Chlordiazepoxide. |
| Nov 16, 2015 | Z-0539-2016 | — | terminated | Ameditechs Drugs of Abuse Tests listed above have shown reduced reactivity for up to two (2) of the nineteen (19) Benzodiazepine (BZO) compounds for which specificity information is provided in the product insert. The particular BZO compounds for which there may be reduced reactivity are Clonazepam and Chlordiazepoxide. |
| Nov 16, 2015 | Z-0519-2016 | — | terminated | Ameditechs Drugs of Abuse Tests listed above have shown reduced reactivity for up to two (2) of the nineteen (19) Benzodiazepine (BZO) compounds for which specificity information is provided in the product insert. The particular BZO compounds for which there may be reduced reactivity are Clonazepam and Chlordiazepoxide. |
| Nov 16, 2015 | Z-0540-2016 | — | terminated | Ameditechs Drugs of Abuse Tests listed above have shown reduced reactivity for up to two (2) of the nineteen (19) Benzodiazepine (BZO) compounds for which specificity information is provided in the product insert. The particular BZO compounds for which there may be reduced reactivity are Clonazepam and Chlordiazepoxide. |
| Nov 16, 2015 | Z-0504-2016 | — | terminated | Ameditechs Drugs of Abuse Tests listed above have shown reduced reactivity for up to two (2) of the nineteen (19) Benzodiazepine (BZO) compounds for which specificity information is provided in the product insert. The particular BZO compounds for which there may be reduced reactivity are Clonazepam and Chlordiazepoxide. |
| Nov 16, 2015 | Z-0523-2016 | — | terminated | Ameditechs Drugs of Abuse Tests listed above have shown reduced reactivity for up to two (2) of the nineteen (19) Benzodiazepine (BZO) compounds for which specificity information is provided in the product insert. The particular BZO compounds for which there may be reduced reactivity are Clonazepam and Chlordiazepoxide. |
| Nov 16, 2015 | Z-0513-2016 | — | terminated | Ameditechs Drugs of Abuse Tests listed above have shown reduced reactivity for up to two (2) of the nineteen (19) Benzodiazepine (BZO) compounds for which specificity information is provided in the product insert. The particular BZO compounds for which there may be reduced reactivity are Clonazepam and Chlordiazepoxide. |
| Nov 16, 2015 | Z-0520-2016 | — | terminated | Ameditechs Drugs of Abuse Tests listed above have shown reduced reactivity for up to two (2) of the nineteen (19) Benzodiazepine (BZO) compounds for which specificity information is provided in the product insert. The particular BZO compounds for which there may be reduced reactivity are Clonazepam and Chlordiazepoxide. |
| Nov 16, 2015 | Z-0542-2016 | — | terminated | Ameditechs Drugs of Abuse Tests listed above have shown reduced reactivity for up to two (2) of the nineteen (19) Benzodiazepine (BZO) compounds for which specificity information is provided in the product insert. The particular BZO compounds for which there may be reduced reactivity are Clonazepam and Chlordiazepoxide. |
| Nov 16, 2015 | Z-0515-2016 | — | terminated | Ameditechs Drugs of Abuse Tests listed above have shown reduced reactivity for up to two (2) of the nineteen (19) Benzodiazepine (BZO) compounds for which specificity information is provided in the product insert. The particular BZO compounds for which there may be reduced reactivity are Clonazepam and Chlordiazepoxide. |
| Nov 16, 2015 | Z-0518-2016 | — | terminated | Ameditechs Drugs of Abuse Tests listed above have shown reduced reactivity for up to two (2) of the nineteen (19) Benzodiazepine (BZO) compounds for which specificity information is provided in the product insert. The particular BZO compounds for which there may be reduced reactivity are Clonazepam and Chlordiazepoxide. |
| Nov 16, 2015 | Z-0532-2016 | — | terminated | Ameditechs Drugs of Abuse Tests listed above have shown reduced reactivity for up to two (2) of the nineteen (19) Benzodiazepine (BZO) compounds for which specificity information is provided in the product insert. The particular BZO compounds for which there may be reduced reactivity are Clonazepam and Chlordiazepoxide. |
| Nov 16, 2015 | Z-0511-2016 | — | terminated | Ameditechs Drugs of Abuse Tests listed above have shown reduced reactivity for up to two (2) of the nineteen (19) Benzodiazepine (BZO) compounds for which specificity information is provided in the product insert. The particular BZO compounds for which there may be reduced reactivity are Clonazepam and Chlordiazepoxide. |
| Nov 16, 2015 | Z-0528-2016 | — | terminated | Ameditechs Drugs of Abuse Tests listed above have shown reduced reactivity for up to two (2) of the nineteen (19) Benzodiazepine (BZO) compounds for which specificity information is provided in the product insert. The particular BZO compounds for which there may be reduced reactivity are Clonazepam and Chlordiazepoxide. |
| Nov 16, 2015 | Z-0498-2016 | — | terminated | Ameditechs Drugs of Abuse Tests listed above have shown reduced reactivity for up to two (2) of the nineteen (19) Benzodiazepine (BZO) compounds for which specificity information is provided in the product insert. The particular BZO compounds for which there may be reduced reactivity are Clonazepam and Chlordiazepoxide. |
| Nov 16, 2015 | Z-0486-2016 | — | terminated | Ameditechs Drugs of Abuse Tests listed above have shown reduced reactivity for up to two (2) of the nineteen (19) Benzodiazepine (BZO) compounds for which specificity information is provided in the product insert. The particular BZO compounds for which there may be reduced reactivity are Clonazepam and Chlordiazepoxide. |
| Nov 16, 2015 | Z-0495-2016 | — | terminated | Ameditechs Drugs of Abuse Tests listed above have shown reduced reactivity for up to two (2) of the nineteen (19) Benzodiazepine (BZO) compounds for which specificity information is provided in the product insert. The particular BZO compounds for which there may be reduced reactivity are Clonazepam and Chlordiazepoxide. |
| Nov 16, 2015 | Z-0508-2016 | — | terminated | Ameditechs Drugs of Abuse Tests listed above have shown reduced reactivity for up to two (2) of the nineteen (19) Benzodiazepine (BZO) compounds for which specificity information is provided in the product insert. The particular BZO compounds for which there may be reduced reactivity are Clonazepam and Chlordiazepoxide. |
| Nov 16, 2015 | Z-0497-2016 | — | terminated | Ameditechs Drugs of Abuse Tests listed above have shown reduced reactivity for up to two (2) of the nineteen (19) Benzodiazepine (BZO) compounds for which specificity information is provided in the product insert. The particular BZO compounds for which there may be reduced reactivity are Clonazepam and Chlordiazepoxide. |
| Nov 16, 2015 | Z-0535-2016 | — | terminated | Ameditechs Drugs of Abuse Tests listed above have shown reduced reactivity for up to two (2) of the nineteen (19) Benzodiazepine (BZO) compounds for which specificity information is provided in the product insert. The particular BZO compounds for which there may be reduced reactivity are Clonazepam and Chlordiazepoxide. |
| Nov 16, 2015 | Z-0502-2016 | — | terminated | Ameditechs Drugs of Abuse Tests listed above have shown reduced reactivity for up to two (2) of the nineteen (19) Benzodiazepine (BZO) compounds for which specificity information is provided in the product insert. The particular BZO compounds for which there may be reduced reactivity are Clonazepam and Chlordiazepoxide. |
| Nov 16, 2015 | Z-0510-2016 | — | terminated | Ameditechs Drugs of Abuse Tests listed above have shown reduced reactivity for up to two (2) of the nineteen (19) Benzodiazepine (BZO) compounds for which specificity information is provided in the product insert. The particular BZO compounds for which there may be reduced reactivity are Clonazepam and Chlordiazepoxide. |
| Nov 16, 2015 | Z-0541-2016 | — | terminated | Ameditechs Drugs of Abuse Tests listed above have shown reduced reactivity for up to two (2) of the nineteen (19) Benzodiazepine (BZO) compounds for which specificity information is provided in the product insert. The particular BZO compounds for which there may be reduced reactivity are Clonazepam and Chlordiazepoxide. |
| Oct 20, 2015 | Z-0317-2016 | — | terminated | Ameditech is recalling drug abuse tests because they have shown reduced reactivity. |
| Oct 20, 2015 | Z-0298-2016 | — | terminated | Ameditech is recalling drug abuse tests because they have shown reduced reactivity. |
| Oct 20, 2015 | Z-0315-2016 | — | terminated | Ameditech is recalling drug abuse tests because they have shown reduced reactivity. |
| Oct 20, 2015 | Z-0308-2016 | — | terminated | Ameditech is recalling drug abuse tests because they have shown reduced reactivity. |
| Oct 20, 2015 | Z-0311-2016 | — | terminated | Ameditech is recalling drug abuse tests because they have shown reduced reactivity. |
| Oct 20, 2015 | Z-0300-2016 | — | terminated | Ameditech is recalling drug abuse tests because they have shown reduced reactivity. |
| Oct 20, 2015 | Z-0309-2016 | — | terminated | Ameditech is recalling drug abuse tests because they have shown reduced reactivity. |
| Oct 20, 2015 | Z-0306-2016 | — | terminated | Ameditech is recalling drug abuse tests because they have shown reduced reactivity. |
| Oct 20, 2015 | Z-0312-2016 | — | terminated | Ameditech is recalling drug abuse tests because they have shown reduced reactivity. |
| Oct 20, 2015 | Z-0305-2016 | — | terminated | Ameditech is recalling drug abuse tests because they have shown reduced reactivity. |
| Oct 20, 2015 | Z-0304-2016 | — | terminated | Ameditech is recalling drug abuse tests because they have shown reduced reactivity. |
| Oct 20, 2015 | Z-0299-2016 | — | terminated | Ameditech is recalling drug abuse tests because they have shown reduced reactivity. |
| Oct 20, 2015 | Z-0302-2016 | — | terminated | Ameditech is recalling drug abuse tests because they have shown reduced reactivity. |
| Oct 20, 2015 | Z-0307-2016 | — | terminated | Ameditech is recalling drug abuse tests because they have shown reduced reactivity. |